Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MethMax trial
2023-507714-27-00Phase 4Authorised
- Sponsor
- Medical University of Vienna, Diakonhjemmet Sykehus AS, Academisch Ziekenhuis Leiden, Karolinska University Hospital
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, single-blind trial of methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Medical University of Vienna, Diakonhjemmet Sykehus AS, Academisch Ziekenhuis Leiden, Karolinska University Hospital. Primary endpoint: CDAI remission at week 24. Planned start Apr 2024; status: authorised.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-507714-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507714-27-00.